DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jzd4jf/generic_drug) has announced the addition of the "Generic Drug ...
This update is a follow-up to the FDA Drug Safety Communication of 12/7/2011: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate ...
The Food and Drug Administration has granted Alembic permission for Dabigatran Etexilate Capsules, 110 mg, which is the generic of Boehringer Ingelheim’s Pradaxa. Dabigatran Etexilate capsules 110 mg ...
Boehringer Ingelheim's Pradaxa blood clot preventer has been associated with a slightly higher risk of heart attack or acute coronary syndrome, according to results of a meta-analysis of several ...
Patients with a faulty heartbeat want Pradaxa - and their clinicians want them to have it, too. You can understand why - when the UK authorities licensed the drug for treating atrial fibrillation in ...
Ridgefield, CT, April 6, 2015 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) filed a supplemental New Drug Application (sNDA) for ...
The FDA announced today that it was initiating a safety review of dabigatran (Pradaxa, Boehringer Ingelheim). The review was prompted by reports of serious bleeding events in people taking the drug.
Alembic has received the Food and Drug Administration’s permission for Dabigatran Etexilate Capsules, 75 mg and 150 mg and tentative approval for Dabigatran Etexilate Capsules, 110 mg. The approved ...
The Food and Drug Administration was “lax” and “permissive” in its review of a blood-thinning drug designed to prevent strokes and clots in patients with a heart condition affecting millions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback